Inflammatory bowel disease (IBD): Limited treatments options

Inflammatory bowel disease (IBD), including its two main forms Crohn’s disease (CD) and ulcerative colitis (UC), is one of the most common inflammatory conditions affecting the gastrointestinal tract. While the prevalence of this chronic and incurable intestinal disorder is increasing worldwide, the mechanisms involved are poorly understood. This knowledge gap led to the absence of cure, limiting therapeutics schemes to symptoms relief through preventive treatment.

T-Cell Bispecific antibodies (TCBs): a promising immunotherapy

Immunotherapy has revolutionized cancer treatment by harnessing the body’s own immune system to recognize and destroy tumour cells. Among these approaches, T-Cell bispecific antibodies (TCBs) have emerged as a powerful new class of therapeutics. TCBs are engineered to bind both to a T-Cell and to a specific antigen on a target cell, leading to T-Cell–mediated killing of  cells expressing the target. Despite their potential, such treatments present a high risk of immune related adverse events, including on-target/off-tumour toxicity when they bind to healthy tissues that express  the same target.

Interstitial Lung Diseases (ILD) and Idiopathic Pulmonary Fibrosis (IPF)

Interstitial lung diseases are a group of disorders characterized by progressive scarring of the lung tissue. One of the most common and severe forms is Idiopathic Pulmonary Fibrosis, where the increase of thickness and stiffness of the tissue lead to impaired of lung function. Even if there are currently two drugs available to slow down the disease progression, Pirfenidone and Nintedanib, none of them allow to reverse the damage caused by IPF.